Loading clinical trials...

Interleukin (IL)-13 as a Marker in Pediatrics Asthma | Clinical Trials | Clareo Health

COMPLETED

Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Cytokine Production in Children With Asthma.

NCT00968305•Rush University Medical Center

Summary

Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.

Detailed Description

This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum IgE levels in African American children with clinically diagnosed asthma

Eligibility

Age

8 - 15 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•African-American race, born in the U.S.
•Age 8-15 years
•Clinical diagnosis of asthma
•Subject is able to understand and follow verbal instructions in English

Exclusion Criteria

•Asthma exacerbation in the 4 weeks preceding the research visit
•Oral/IV steroid use in the 4 weeks preceding the research visit
•Upper or lower respiratory tract infection in the 4 weeks preceding the research visit
•Antibiotic use in the 4 weeks preceding the research visit
•Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing)
•Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Locations (1)

Rush University Medical Center; Clinic: University Consultants in Allergy and Immunology

Chicago, Illinois, United States

Key Dates

Start Date

November 1, 2008

Primary Completion Date

August 1, 2009

Completion Date

August 1, 2009

Last Updated

August 28, 2009

Enrollment

ACTUAL participants

Conditions

Asthma

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173

Asthma

View study

RECRUITINGNA

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma